Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference
Krystal Biotech will join the 2026 Cantor Global Healthcare Conference with a webcasted fireside chat and investor meetings on September 10.
Rhea-AI Summary
Krystal Biotech (KRYS) will participate in the 2026 Cantor Global Healthcare Conference on September 10, 2026, in New York.
Management is scheduled for a fireside chat at 3:55 p.m. ET and will also host investor meetings during the day. A webcast of the presentation will be available starting at 3:55 p.m. ET and posted in the Investors section of the company’s website.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 03 | 2Q earnings | Positive | -8.4% | Quarterly revenue growth, profitability, cash balance, and full-year expense guidance |
| Jul 23 | Earnings date | Neutral | +2.4% | Company scheduled second-quarter results and an 8:30 a.m. ET conference call |
| Jul 20 | Index inclusion | Neutral | -0.1% | Krystal was scheduled to join the S&P MidCap 400 effective July 24 |
| May 18 | UK approval | Positive | -4.8% | UK MHRA marketing authorization for VYJUVEK in dystrophic epidermolysis bullosa |
| May 07 | Conference presentation | Neutral | +2.7% | Company announced a BofA healthcare conference fireside chat and investor meetings |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive news was followed by declines in two cases, including the August 3 earnings release at -8.37% and the May 18 approval at -4.75%, while conference-related announcements were followed by gains.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PITTSBURGH, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 2026 Cantor Global Healthcare Conference on September 10, 2026, in New York. Management will take part in a fireside chat scheduled at 3:55 pm ET and host investor meetings throughout the day.
A webcast of the presentation will be available here beginning at 3:55 pm ET on Thursday, September 10, 2026 and will be posted on the Investors section of the Company’s website.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. Visit www.krystalbio.com to learn more or follow us on LinkedIn and X.
CONTACT
Investors and Media:
Stéphane Paquette, PhD
Krystal Biotech
spaquette@krystalbio.com
